144 related articles for article (PubMed ID: 23689977)
1. Characterization of the Yoshida sarcoma: a model of cancer cachexia.
Honors MA; Kinzig KP
Support Care Cancer; 2013 Oct; 21(10):2687-94. PubMed ID: 23689977
[TBL] [Abstract][Full Text] [Related]
2. Diet-induced obesity and insulin resistance spur tumor growth and cancer cachexia in rats bearing the Yoshida sarcoma.
Honors MA; Kinzig KP
Nutr Cancer; 2014; 66(5):872-8. PubMed ID: 24897498
[TBL] [Abstract][Full Text] [Related]
3. Chronic exendin-4 treatment prevents the development of cancer cachexia symptoms in male rats bearing the Yoshida sarcoma.
Honors MA; Kinzig KP
Horm Cancer; 2014 Feb; 5(1):33-41. PubMed ID: 24101584
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency?
Fontes-Oliveira CC; Busquets S; Toledo M; Penna F; Paz Aylwin M; Sirisi S; Silva AP; Orpí M; García A; Sette A; Inês Genovese M; Olivan M; López-Soriano FJ; Argilés JM
Biochim Biophys Acta; 2013 Mar; 1830(3):2770-8. PubMed ID: 23200745
[TBL] [Abstract][Full Text] [Related]
5. BARD1 content correlates with increased DNA fragmentation associated with muscle wasting in tumour-bearing rats.
Irminger-Finger I; Busquets S; Calabrio F; López-Soriano FJ; Argilés JM
Oncol Rep; 2006 Jun; 15(6):1425-8. PubMed ID: 16685375
[TBL] [Abstract][Full Text] [Related]
6. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.
Busquets S; Figueras MT; Fuster G; Almendro V; Moore-Carrasco R; Ametller E; Argilés JM; López-Soriano FJ
Cancer Res; 2004 Sep; 64(18):6725-31. PubMed ID: 15374990
[TBL] [Abstract][Full Text] [Related]
7. Lack of effect of the cytokine suppressive agent FR167653 on tumour growth and cachexia in rats bearing the Yoshida AH-130 ascites hepatoma.
Busquets S; Alvarez B; van Royen M; Carbó N; López-Soriano FJ; Argilés JM
Cancer Lett; 2000 Aug; 157(1):99-103. PubMed ID: 10893448
[TBL] [Abstract][Full Text] [Related]
8. Anorexia-cachexia syndrome in hepatoma tumour-bearing rats requires the area postrema but not vagal afferents and is paralleled by increased MIC-1/GDF15.
Borner T; Arnold M; Ruud J; Breit SN; Langhans W; Lutz TA; Blomqvist A; Riediger T
J Cachexia Sarcopenia Muscle; 2017 Jun; 8(3):417-427. PubMed ID: 28025863
[TBL] [Abstract][Full Text] [Related]
9. Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats.
Combaret L; Rallière C; Taillandier D; Tanaka K; Attaix D
Mol Biol Rep; 1999 Apr; 26(1-2):95-101. PubMed ID: 10363654
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats.
Carbó N; López-Soriano J; Costelli P; Busquets S; Alvarez B; Baccino FM; Quinn LS; López-Soriano FJ; Argilés JM
Br J Cancer; 2000 Aug; 83(4):526-31. PubMed ID: 10945502
[TBL] [Abstract][Full Text] [Related]
11. Akt activation by insulin treatment attenuates cachexia in Walker-256 tumor-bearing rats.
de Fatima Silva F; de Morais H; Ortiz Silva M; da Silva FG; Vianna Croffi R; Serrano-Nascimento C; Rodrigues Graciano MF; Rafael Carpinelli A; Barbosa Bazotte R; de Souza HM
J Cell Biochem; 2020 Nov; 121(11):4558-4568. PubMed ID: 32056265
[TBL] [Abstract][Full Text] [Related]
12. Alterations of lipid and cholesterol metabolism in cachectic tumor-bearing rats are prevented by insulin.
Costelli P; Tessitore L; Batetta B; Mulas MF; Spano O; Pani P; Baccino FM; Dessì S
J Nutr; 1999 Mar; 129(3):700-6. PubMed ID: 10082777
[TBL] [Abstract][Full Text] [Related]
13. Differential structural features in soleus and gastrocnemius of carnitine-treated cancer cachectic rats.
Busquets S; Pérez-Peiró M; Salazar-Degracia A; Argilés JM; Serpe R; Rojano-Toimil A; López-Soriano FJ; Barreiro E
J Cell Physiol; 2020 Jan; 235(1):526-537. PubMed ID: 31241186
[TBL] [Abstract][Full Text] [Related]
14. Alterations in whole body, muscle, liver, and tumor tissue protein synthesis and degradation in Novikoff hepatoma and Yoshida sarcoma tumor growth studied in vivo.
Tayek JA; Blackburn GL; Bistrian BR
Cancer Res; 1988 Mar; 48(6):1554-8. PubMed ID: 3345528
[TBL] [Abstract][Full Text] [Related]
15. Effects of the phosphodiesterase-IV inhibitor EMD 95832/3 on tumour growth and cachexia in rats bearing the Yoshida AH-130 ascites hepatoma.
Meijsing B; Carbó N; López-Soriano FJ; Argilés JM
Cancer Lett; 2002 Dec; 188(1-2):53-8. PubMed ID: 12406548
[TBL] [Abstract][Full Text] [Related]
16. Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation.
Quan-Jun Y; Yan H; Yong-Long H; Li-Li W; Jie L; Jin-Lu H; Jin L; Peng-Guo C; Run G; Cheng G
Mol Cancer Ther; 2017 Feb; 16(2):334-343. PubMed ID: 27599525
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological interference with tissue hypercatabolism in tumour-bearing rats.
Tessitore L; Costelli P; Baccino FM
Biochem J; 1994 Apr; 299 ( Pt 1)(Pt 1):71-8. PubMed ID: 8166661
[TBL] [Abstract][Full Text] [Related]
18. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia.
DeBoer MD; Zhu XX; Levasseur P; Meguid MM; Suzuki S; Inui A; Taylor JE; Halem HA; Dong JZ; Datta R; Culler MD; Marks DL
Endocrinology; 2007 Jun; 148(6):3004-12. PubMed ID: 17347304
[TBL] [Abstract][Full Text] [Related]
19. Human pancreatic cancer xenografts recapitulate key aspects of cancer cachexia.
Delitto D; Judge SM; Delitto AE; Nosacka RL; Rocha FG; DiVita BB; Gerber MH; George TJ; Behrns KE; Hughes SJ; Wallet SM; Judge AR; Trevino JG
Oncotarget; 2017 Jan; 8(1):1177-1189. PubMed ID: 27901481
[TBL] [Abstract][Full Text] [Related]
20. Rosiglitazone and imidapril alone or in combination alleviate muscle and adipose depletion in a murine cancer cachexia model.
Chen SZ; Xiao JD
Tumour Biol; 2014 Jan; 35(1):323-32. PubMed ID: 23959470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
